ORMPHealthcare · BiotechnologyORMP Stock Forecast: Oramed Pharmaceuticals, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 81 of 100 as at 7 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.
ORMP stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Oramed Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (86): The shares have been drifting up relative to others.
Accruals (10): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
ORMP stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ORMP, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 20 May 2024 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 17 May 2023 | Canaccord Genuity | Maintains | Hold | — |
| 17 Jan 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 12 Jan 2023 | Canaccord Genuity | Downgrade | Hold | — |
| 16 May 2022 | Aegis Capital | Maintains | Buy | — |
| 18 Feb 2022 | Cantor Fitzgerald | Initiates | Overweight | — |
| 30 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 Nov 2021 | Aegis Capital | Maintains | Buy | — |
| 29 July 2021 | Canaccord Genuity | Maintains | Buy | — |
| 8 June 2021 | Aegis Capital | Maintains | Buy | — |
| 20 Apr 2021 | Canaccord Genuity | Initiates | Buy | — |
| 9 Feb 2021 | National Securities Corporation | Initiates | Buy | — |
| 27 Jan 2021 | Aegis Capital | Maintains | Buy | — |
| 13 July 2020 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 June 2020 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Sept 2019 | Ladenburg Thalmann | Initiates | Buy | — |
| 19 Nov 2015 | FBR Capital | Initiates | Outperform | — |
| 1 Oct 2015 | H.C. Wainwright | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ORMP appears on the weeks it earns a place.
ORMP vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Sept 2026, Oramed Pharmaceuticals, Inc. returned +142.1% against +20.0% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ORMP analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Oramed Pharmaceuticals, Inc. (ORMP) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 1.2×
- Price / sales
- 104.2×
- Price / book
- 0.7×
- EV / EBITDA
- −11.0×
Cheaper than 70% of US stocks
Cheaper than 4% of US stocks
Cheaper than 83% of US stocks
Cheaper than 85% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- 488.2%
- Gross margin
- —
- Operating margin
- 3766.2%
- Net margin
- 0.7%
Higher than 95% of US stocks
Higher than 99% of US stocks
Higher than 48% of US stocks
- Return on equity
- 74.2%
- Return on assets
- −3.4%
- Dividend yield
- 5.0%
Higher than 95% of US stocks
Higher than 34% of US stocks
Higher than 83% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
Oramed Pharmaceuticals, Inc. (ORMP) statistics: revenue, profit & scale
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Oramed Pharmaceuticals, Inc. has a market value of $208.4M and an enterprise value of $158.5M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: $174.9M.
Free cash flow in the twelve months to 30 June 2026: −$7.1M.
Trailing P/E: 1.2×; forward P/E: −62.6× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 4.99%, paying out 6% of earnings.
Oramed Pharmaceuticals, Inc. employs 0 people.
Data provided by Twelve Data
ORMP vs competitors
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Oramed Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Frequently asked questions about ORMP stock
How does Ticker Nerd's model rank ORMP?
As at 7 Sept 2026, Oramed Pharmaceuticals, Inc. ranks 81 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (86 of 100).
What is the ORMP stock forecast for 2030?
No analyst covering Oramed Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ORMP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
How has ORMP stock performed over the past year?
Oramed Pharmaceuticals, Inc. returned +142.1% over the 12 months to 4 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Oramed Pharmaceuticals, Inc. do?
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on oral drug delivery solutions for medications that are traditionally administered by injection.
About Oramed Pharmaceuticals, Inc.
Oramed Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on oral drug delivery solutions for medications that are traditionally administered by injection. The company develops proprietary technologies designed to make therapeutic proteins and peptides easier to administer in capsule form, with a particular emphasis on diabetes-related treatments and other biologic therapies. Its current product and development portfolio includes oral insulin programs, along with partnering and licensing activities that support broader applications for its delivery platform. Oramed Pharmaceuticals Inc. also participates in strategic collaborations and investment transactions tied to its biomedical assets, reflecting a business model that combines drug development with portfolio-based value creation. Headquartered in New York, the company operates within the pharmaceuticals and biotechnology market, where oral delivery platforms can play an important role in improving convenience and expanding the usability of complex medicines.
CEO Mr. Nadav Kidron Esq. · United States · https://oramed.com